Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
1200133-34-1	VCH-916 VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.
1204416-97-6	TMC647055 28-Cyclohexyl-22-methoxy-10,16-dimethyl-9,9-dioxo-13-oxa-9lambda6-thia-1,8,10,16-tetrazapentacyclo[16.8.1.12,6.13,26.020,25]nonacosa-2,4,6(29),18,20(25),21,23,26(28)-octaene-7,17-dione (CAS# 1204416-97-6 ) is a useful research chemical.
1206524-86-8	MK-5172 potassium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
121104-96-9	6-O-butyl castanospermine Celgosivir, an effective α-glucosidase I inhibitor, has been found to be related to viral maturation and is still under Phase I/II trial against Dengue. IC50: 16 and 47 umol/L (through plaque assay and a cytopathic assay).
1217338-97-0	BMS-929075
1231747-08-2	PSI-353661
1231747-17-3	PSI-352938 PSI-352938 is an inhibitor of hepatitis C virus (HCV) nucleotide.
123307-75-5	RBT-9
123402-21-1	3′-Deoxy-3′-fluoroguanosine 3'-Deoxy-3'-fluoroguanosine, an antiviral agent, is a modified nucleoside used in biochemical research and therapeutic development to enhance the stability and binding properties of oligonucleotides. The removal of the 3' hydroxyl group (deoxy) and substitution with a fluorine atom at the 3' position increase resistance to enzymatic degradation and improve the molecule's overall stability, making it useful in the development of stable therapeutic agents and the study of nucleic acid interactions.
1234402-77-7	CpG ODN 10101 CpG ODN 10101 is a synthetic oligodeoxynucleotide (ODN) that induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
1234490-83-5	INX 08189 BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection.
1241946-89-3	Simeprevir sodium salt Simeprevir is an orally bioavailable inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It has been approved in combination with peginterferon-alfa and ribavirin for the treatment of HCV and HBV infections.
1248581-07-8	PTC 725
1252679-52-9	ITX-5061 HCl This active molecular is a scavenger receptor B1 antagonist under the development by iTherX Pharmaceuticals for the treatment of Hepatitis C. ITX-5061 shows a special mechanism of action that prevents the hepatitis C virus from entering liver cells. Preclinical studies have shown that ITX-5061 can prevent virus binding/fusion and cell to cell spread. In Jan 2015, Phase-II clinical trials in Hepatitis C in USA was on-going.
1256388-51-8	Ledipasvir Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
1256390-53-0	GSK2236805
1256490-42-2	Sofosbuvir metabolite GS331007-[13C,d3] An isotope labelled metabolite of Sofosbuvir. Sofosbuviis a medication used for the treatment of hepatitis C.
1256751-11-7	Boceprevir-[d9] Boceprevir-[d9] is a stable isotopic labelled compound of Boceprevir. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
1258226-87-7	Ombitasvir Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 respectively.
1303533-81-4	Ravidasvir hydrochloride Avidasvir is a second-generation Hepatitis C virus NS 5 protein inhibitor. In Sep 2016, Phase-II/III clinical trials in Hepatitis C in Malaysia was on-going.

※ Please kindly note that our services are for research use only.